Objective: This investigation focuses on conducting a comprehensive in vitro standard evaluation of ten different Clopidogrel (75mg) brands available in Karachi, Pakistan. Methodology: The study involved pharmacopoeial tests on ten Clopidogrel tablet brands, including weight variation, friability, disintegration, dissolution, and assay. Non-pharmacopoeial tests measured thickness, diameter, and hardness. Model-dependent approaches used first-order kinetics, Higuchi, Hixson Crowell, and Weibull models. Model-independent approaches calculated the difference (f1) and similarity (f2) factors for dissolution data analysis. Results: The average weight variation of all ten coded Clopidogrel brands fell within the USP specification of ±7.5% deviation (225.9-356.1 mg). Measurements of hardness, thickness, and diameter met specified limits outlined by USP. Disintegration times of 2-8 minutes complied with the USP standard for film-coated tablets. Friability ranged from 0.02% to 0.3%, within the standard limit, indicating tablets' sufficient mechanical strength. Assay studies revealed Clopidogrel content within the range of 98.7% to 101.30%, aligning with USP assay monograph limits. Multiple point dissolution studies in 0.1N HCl showed drug release ranging from 90.9% to 99.8%, meeting USP specifications. Similarity factor (f1) and dissimilarity factor (f2) values were within limits, reinforcing bioequivalence. Kinetic models, including first order, Hixon and Crowell were applied, and all coded brands demonstrated acceptable r2 values. Conclusion: The study successfully implemented pharmacopeial and non-pharmacopeial tests on ten Clopidogrel (75mg) brands available in Karachi, Pakistan, demonstrating compliance with USP specifications. While the results suggest the suitability of these formulations for therapeutic use, a larger-scale study is recommended for further validation and understanding.